J
11.72
-0.67 (-5.41%)
| Previous Close | 12.39 |
| Volume | 346,342 |
| Price / Sales | 32.42 |
| Price / Book | 0.810 |
| 52 Weeks Range |
| Operating Margin (TTM) | -1,216.61% |
| Diluted EPS (TTM) | -1.36 |
| Quarterly Revenue Growth (YOY) | -100.00% |
| Total Debt/Equity (MRQ) | 2.23% |
| Current Ratio (MRQ) | 58.47 |
| Operating Cash Flow (TTM) | -46.00 M |
| Levered Free Cash Flow (TTM) | -27.01 M |
| Return on Assets (TTM) | -8.16% |
| Return on Equity (TTM) | -9.32% |
AIStockmoo Score
| Value 35% | 0.0 |
| AI Insight info | NA |
| Relative Valuation info | NA |
| Financial Health info | 0.0 |
| Timing 35% | -2.5 |
| AI Technical info | NA |
| Technical Oscillators info | -2.5 |
| Technical Moving Averages info | -2.5 |
| Smart Money 30% | 0.0 |
| Analyst Consensus info | 0.0 |
| Insider Activity info | NA |
| News Mood info | NA |
| Environment | ×1.21 |
| Macro Environment info | -3.3 |
| Sector vs Market (6M) | -23.0% |
| Pillar Agreement | ×1.00 |
| Not in score | |
| Price Volatility info | 0.8 |
| Final Score | -1.06 |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Bullish |
| Biotechnology (Global) | Mixed | Bullish | |
| Stock | Janux Therapeutics, Inc. | Mixed | Bearish |
Similar Stocks
| Stock | Market Cap | DY | P/E (TTM) | P/B |
|---|---|---|---|---|
| JANX | - | - | - | 0.810 |
| TRML | 1 B | - | - | 4.76 |
| ABEO | - | - | - | 1.04 |
| CTNM | - | - | - | 1.69 |
| FTRE | - | - | - | 3.88 |
| DBVT | - | - | - | 4.87 |
Select this tab to load the latest available analysis.
|
Janux Therapeutics Inc is a clinical-stage biopharmaceutical company developing tumor-activated immunotherapies for cancer. The proprietary technology of the company has enabled the development of distinct bispecific platforms: Tumor Activated T Cell Engagers (TRACTr), Tumor Activated Immunomodulators (TRACIr), and Adaptive Immune Response Modulator (ARM) platforms. The TRACTr platform produces T cell engagers (TCEs) with a tumor antigen-binding domain and a CD3 T cell binding domain, while the TRACIr platform produces bispecifics with a tumor antigen-binding domain and a costimulatory CD28 binding domain. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Core |
| % Held by Insiders | 6.69% |
| % Held by Institutions | 113.78% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Prosight Management, Lp | 30 Jun 2026 | 3,804,481 |
No data within this time range.
No data within this time range.
| Date | Type | Details |
|---|---|---|
| 09 Nov 2026 | Yahoo Finance |
Janux Reports Deep B-Cell Depletion in Initial Phase 1 Trial of JANX011; Shares Fall
Janux Therapeutics (JANX) said Monday that initial results from its phase 1 study of JANX011 in heal… |
| 09 Nov 2026 | Yahoo Finance |
Janux Therapeutics Stock In Focus As Loss Narrows And Phase 1 Data Nears
Janux Therapeutics reported third quarter 2026 results with a net loss of US$21.57 million and basic loss per share of US$0.34, and noted plans to share initial Phase 1 data for JANX011 in healthy volunteers after the period ended. The business reduced its net loss over both the quarter and the… |
| 09 Nov 2026 | Yahoo Finance |
Janux Therapeutics Announces Positive Initial Phase 1 Data for JANX011 in Healthy Volunteers, Supporting Planned Development in Patients with Autoimmune Disease
SAN DIEGO, November 09, 2026--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today announced initial clinical results from the Phase 1 study of JANX011 in healthy volunteers and outlined its planned… |
| 07 Nov 2026 | Yahoo Finance |
Janux Therapeutics (JANX) Earnings Beat Brings Its Pricey Valuation Back Into Focus
Janux Therapeutics earnings surprise and stock reaction The latest quarter was a catalyst. Janux Therapeutics (JANX) reported a narrower net loss and a smaller loss per share than a year ago, while revenue exceeded analyst expectations. Investors have reacted quickly to the earnings surprise, with… |
| 05 Nov 2026 | Yahoo Finance |
Janux Therapeutics Reports Third Quarter 2026 Financial Results and Business Highlights
SAN DIEGO, November 05, 2026--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies, today reported financial results for the quarter ended September 30, 2026, and provided a business update. |
| 05 Nov 2026 | Yahoo Finance |
Janux Therapeutics, Inc. (JANX) Reports Q3 Loss, Beats Revenue Estimates
Janux Therapeutics (JANX) delivered earnings and revenue surprises of +24.44% and +34.12%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 02 Nov 2026 | Yahoo Finance |
Janux Therapeutics to Host Virtual Event Presenting Initial Phase 1 Clinical Data for JANX011 in Healthy Volunteers
SAN DIEGO, November 02, 2026--Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biopharmaceutical company developing next-generation immunotherapies, today announced that it will host a virtual event on Monday, November 9, 2026, at 8:30 a.m. ET. |
| 29 Oct 2026 | Yahoo Finance |
Janux Therapeutics (JANX) Stock Looks Above Fair Value Based On Sales
Janux Therapeutics has seen a steep mix of gains and setbacks in recent years, which puts fresh attention on a basic question for you as a shareholder or potential buyer. Is the current US$18.05 share price adequately supported by the company’s sales, given how sharply the stock has moved over… |
| 27 Oct 2026 | Yahoo Finance |
Ensign Group (ENSG) Beats Q3 Earnings Estimates
Ensign Group (ENSG) delivered earnings and revenue surprises of +4.64% and -0.71%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock? |
| 13 Oct 2026 | Yahoo Finance |
Janux Therapeutics (JANX), What Is Drawing Fresh Attention Now?
Janux Therapeutics (JANX) has drawn fresh attention after recent trading left the stock at $18.15, with returns over the past month, past 3 months, and year telling very different stories for investors. Recent trading has been choppy, with a 9.73% 7 day share price return and a 32.97% year to date… |
| 10 Oct 2026 | Yahoo Finance |
Janux Therapeutics (JANX) Stock May Look Overvalued After Its 110% Run
Janux Therapeutics has seen a sharp mix of gains and setbacks in recent years, which puts a spotlight on whether its current share price lines up with what its sales can support. With such a volatile track record, the key issue for you as an investor is how much revenue power the market is… |
| 30 Sep 2026 | Yahoo Finance |
Iovance Biotherapeutics (IOVA) Surges 31.5%: Is This an Indication of Further Gains?
Iovance Biotherapeutics (IOVA) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term. |
| 29 Sep 2026 | Yahoo Finance |
Is Janux’s Dual JANX013–JANX007 Trial Advancing a Durable Precision Oncology Platform for JANX?
Janux Therapeutics has recently dosed the first patient in its Phase 1 trial evaluating JANX013 in combination with JANX007 for metastatic castration-resistant prostate cancer, marking a new step in its clinical pipeline. This trial brings fresh attention to Janux Therapeutics’ prostate cancer… |
| 27 Sep 2026 | Yahoo Finance |
Janux Therapeutics (JANX) Advances Prostate Cancer Trial While Valuation Still Looks Pricey
Janux Therapeutics (JANX) just hit a clinical milestone, dosing the first patient in its Phase 1 trial of JANX013 with JANX007 for metastatic castration-resistant prostate cancer. This development is sharpening investor focus on this prostate cancer platform. The JANX share price has cooled in the… |
| 16 Sep 2026 | Yahoo Finance |
The Zacks Analyst Blog Highlights Pfizer, Novartis, Candel and Janux
Prostate cancer awareness spotlights Pfizer's Xtandi, Novartis' Pluvicto and clinical-stage programs from Candel and Janux. |
| 15 Sep 2026 | Yahoo Finance |
4 Prostate Cancer Drug Stocks to Watch During Awareness Month
Pfizer, Novartis, Janux Therapeutics and Candel Therapeutics offer varied prostate-cancer exposure, with established drugs and clinical or regulatory catalysts. |
| 14 Sep 2026 | Yahoo Finance |
Janux Therapeutics Announces First Patient Dosed in Phase 1 Study of JANX013
SAN DIEGO, September 14, 2026--Janux Therapeutics, Inc. (Nasdaq: JANX), a clinical-stage biotechnology company developing tumor-activated immunotherapies, today announced that the first patient has been dosed in the Phase 1 clinical trial evaluating JANX013, Janux's novel PSMA-targeted… |
| 24 Aug 2026 | Yahoo Finance |
Here Are Monday’s Top Wall Street Analyst Research Calls: AstraZeneca, Celestica, Chipotle Mexican Grill, Domino’s Pizza, Fortune Brands, Golar LNG, Jersey Mike’s Subs, Roku, and More
Wall Street analysts reshuffled the deck on Monday with a wave of upgrades, downgrades, and fresh initiations spanning pharma giants, fast-casual chains, and streaming players. Find out which names got bullish bets and which lost their analyst backing. |
| 24 Aug 2026 | Yahoo Finance |
Chipotle downgraded, Darden upgraded: Wall Street's top analyst calls
Chipotle downgraded, Darden upgraded: Wall Street's top analyst calls… |
| 21 Aug 2026 | Yahoo Finance |
JANX Shares Gain 19.1% in 3 Months: Here's What You Need to Know
Janux stock climbs 19.1% in three months as pipeline progress, upcoming catalysts and a strong cash position boost investor confidence. |
| Show more | ||
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2026 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |